- Home
- VERA vs PTGX Comparison
VERA vs PTGX Comparison
Compare VERA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERA | PTGX |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 5.4B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | VERA | PTGX |
|---|---|---|
| Price | $47.61 | $85.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $67.67 | ★ $90.56 |
| AVG Volume (30 Days) | ★ 1.9M | 994.3K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $296.47 |
| P/E Ratio | ★ N/A | $124.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.53 | $33.70 |
| 52 Week High | $51.19 | $96.54 |
Technical Indicators
Market Signals| Indicator | VERA | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 73.52 | 45.65 |
| Support Level | $40.38 | $88.30 |
| Resistance Level | $51.19 | $96.54 |
| Average True Range (ATR) | 3.37 | 3.46 |
| MACD | 0.54 | -0.67 |
| Stochastic Oscillator | 80.73 | 11.14 |
Price Performance
Historical ComparisonAbout VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.